×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AIM – aim immunotech inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AIM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/1
09:13 am
aim
AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series [Yahoo! Finance]
Medium
Report
AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series [Yahoo! Finance]
12/1
08:55 am
aim
AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
Low
Report
AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
11/18
04:12 pm
aim
AIM ImmunoTech GAAP EPS of -$1.57 misses by $0.59 [Seeking Alpha]
Neutral
Report
AIM ImmunoTech GAAP EPS of -$1.57 misses by $0.59 [Seeking Alpha]
11/18
08:55 am
aim
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
Medium
Report
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
11/10
10:01 am
aim
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer [Yahoo! Finance]
Medium
Report
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer [Yahoo! Finance]
11/10
08:55 am
aim
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer
Medium
Report
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer
11/4
09:05 am
aim
AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
High
Report
AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
11/3
08:55 am
aim
AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue
Medium
Report
AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/19
07:00 am
aim
Form 8-K AIM ImmunoTech Inc. For: Nov 18
Medium
Report
Form 8-K AIM ImmunoTech Inc. For: Nov 18
11/17
04:36 pm
aim
Form 10-Q AIM ImmunoTech Inc. For: Sep 30
High
Report
Form 10-Q AIM ImmunoTech Inc. For: Sep 30
11/17
06:12 am
aim
Form NT 10-Q AIM ImmunoTech Inc. For: Sep 30
Low
Report
Form NT 10-Q AIM ImmunoTech Inc. For: Sep 30
10/30
05:00 pm
aim
Form 424B5 AIM ImmunoTech Inc.
Medium
Report
Form 424B5 AIM ImmunoTech Inc.
10/29
05:17 pm
aim
Form 8-K AIM ImmunoTech Inc. For: Oct 29
Medium
Report
Form 8-K AIM ImmunoTech Inc. For: Oct 29
10/29
04:31 pm
aim
Form DEF 14A AIM ImmunoTech Inc. For: Oct 29
Medium
Report
Form DEF 14A AIM ImmunoTech Inc. For: Oct 29
10/20
09:16 am
aim
Form 8-K AIM ImmunoTech Inc. For: Oct 20
Low
Report
Form 8-K AIM ImmunoTech Inc. For: Oct 20
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/9
AIM ImmunoTech’s Drug Ampligen to Be Tested by Japan’s National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19
169.9%
9/24 Form S-1/A AIM ImmunoTech Inc. 48.2%
3/3 Form 424B5 AIM ImmunoTech Inc. 32.2%
2/11 AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus 26.2%
2/12 AIM ImmunoTech’s CEO to Appear Live Today on FOX Business Network’s The Claman Countdown and Cheddar’s Opening Bell to Discuss the Potential Role of Ampligen(R) for Use Against the Wuhan 2019 Novel Coronavirus 19.0%
9/19 AIM ImmunoTech Inc. Announces the U.S. Department of Defense’s Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer 18.9%
3/10 Form 424B5 AIM ImmunoTech Inc. 15.7%
12/2 Form 4 AIM ImmunoTech Inc. For: Nov 29 Filed by: EQUELS THOMAS K. 15.6%
11/1 Form 4 AIM ImmunoTech Inc. For: Oct 31 Filed by: APPELROUTH STEWART 13.8%
4/27 Form 8-K AIM ImmunoTech Inc. For: Apr 27 13.6%
9/24 Form S-1/A AIM ImmunoTech Inc. 48.2%
3/3 Form 424B5 AIM ImmunoTech Inc. 32.2%
2/11 AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus 26.2%
2/12 AIM ImmunoTech’s CEO to Appear Live Today on FOX Business Network’s The Claman Countdown and Cheddar’s Opening Bell to Discuss the Potential Role of Ampligen(R) for Use Against the Wuhan 2019 Novel Coronavirus 19.0%
9/19 AIM ImmunoTech Inc. Announces the U.S. Department of Defense’s Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer 18.9%
3/10 Form 424B5 AIM ImmunoTech Inc. 15.7%
12/2 Form 4 AIM ImmunoTech Inc. For: Nov 29 Filed by: EQUELS THOMAS K. 15.6%
11/1 Form 4 AIM ImmunoTech Inc. For: Oct 31 Filed by: APPELROUTH STEWART 13.8%
4/27 Form 8-K AIM ImmunoTech Inc. For: Apr 27 13.6%
TOP News Decliners
9/25
Form S-1/A AIM ImmunoTech Inc.
-44.1%
9/19 AIM Immunotech up 105% premarket after DOD grant for cancer study [Seeking Alpha] -32.3%
2/11 Form 8-K AIM ImmunoTech Inc. For: Feb 11 -28.4%
3/31 AIM ImmunoTech Reports 2019 Year-end Financial Results -24.9%
9/26 Form EFFECT AIM ImmunoTech Inc. -15.3%
2/18 Form 8-K AIM ImmunoTech Inc. For: Feb 18 -12.0%
9/24 Form 8-K AIM ImmunoTech Inc. For: Sep 19 -8.9%
4/6 AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic -8.1%
12/4 Form 8-K AIM ImmunoTech Inc. For: Dec 04 -7.9%
10/10 AIM ImmunoTech Inc. (NYSE: AIM) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. -7.7%
9/19 AIM Immunotech up 105% premarket after DOD grant for cancer study [Seeking Alpha] -32.3%
2/11 Form 8-K AIM ImmunoTech Inc. For: Feb 11 -28.4%
3/31 AIM ImmunoTech Reports 2019 Year-end Financial Results -24.9%
9/26 Form EFFECT AIM ImmunoTech Inc. -15.3%
2/18 Form 8-K AIM ImmunoTech Inc. For: Feb 18 -12.0%
9/24 Form 8-K AIM ImmunoTech Inc. For: Sep 19 -8.9%
4/6 AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic -8.1%
12/4 Form 8-K AIM ImmunoTech Inc. For: Dec 04 -7.9%
10/10 AIM ImmunoTech Inc. (NYSE: AIM) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. -7.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: